MEDCX | VEMBX | MEDCX / VEMBX | |
Total Expense Ratio | 1.81 | 0.50 | 362% |
Annual Report Gross Expense Ratio | 1.82 | 0.50 | 364% |
Fund Existence | 23 years | 9 years | - |
Gain YTD | 6.364 | 8.776 | 73% |
Front Load | N/A | N/A | - |
Min. Initial Investment | 1000 | 3000 | 33% |
Min. Initial Investment IRA | N/A | N/A | - |
Net Assets | 7.48B | 4.73B | 158% |
Annual Yield % from dividends | 4.89 | 6.47 | 76% |
Returns for 1 year | 6.81 | 8.94 | 76% |
Returns for 3 years | 24.91 | 35.20 | 71% |
Returns for 5 years | 5.25 | 15.26 | 34% |
Returns for 10 years | 34.38 | N/A | - |
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
JNDVX | 12.95 | 0.20 | +1.57% |
Janus Henderson U.S. Dividend Income N | |||
NFAAX | 35.08 | 0.54 | +1.56% |
Neuberger Berman Focus A | |||
SBLYX | 78.81 | 1.16 | +1.49% |
ClearBridge Large Cap Growth I | |||
TWQIX | 16.48 | 0.24 | +1.48% |
Transamerica Large Cap Value I | |||
IGFAX | 12.00 | 0.10 | +0.84% |
VY® Morgan Stanley Global Franchise A |